Predictive value of topoisomerase II alpha protein for clinicopathological characteristics and prognosis in early breast cancer

Breast Cancer Res Treat. 2022 Jun;193(2):381-392. doi: 10.1007/s10549-022-06559-7. Epub 2022 Mar 16.

Abstract

Purpose: Topoisomerase II alpha (TOP2A) has been identified as a proliferation marker, of which the most common method for detection is immunohistochemistry (IHC). However, the optimal cut-off of TOP2A expression regarding prognostic value remains controversial. This study was to identify the optimal cut-off value of TOP2A expression and its correlation with clinicopathological variables and prognosis in early stage breast cancer in China.

Methods: Between January 2013 and January 2015, a total of 1084 early breast cancer patients were enrolled. The optimal cut-off of TOP2A expression was assessed using the minimum P value approach. Correlations between TOP2A expression and clinicopathological characteristics were explored by the Spearman's correlation analysis, while the impact of TOP2A expression on disease-free survival (DFS) and overall survival (OS) was evaluated by the Kaplan-Meier methods. Univariate and multivariate Cox regression analyses were executed to identify statistically significant prognostic factors.

Results: The optimal cut-off value of TOP2A was recommended as 15%. Overall, 603 (55.6%) patients were TOP2A over-expression and 481 (44.4%) patients were TOP2A low expression. TOP2A over-expression was in positive associations with a higher Ki67 index (r = 0.83, P < 0.001), HER2 positive (r = 0.26, P < 0.001), a larger tumor size (r = 0.14, P < 0.001), and a higher histologic grade (r = 0.59, P < 0.001), and in a significantly negative correlation with hormone receptor (HR) positive expression (r = - 0.40, P < 0.001) in early breast cancer. TOP2A over-expression significantly associated with worse DFS (P = 0.001) and OS (P < 0.001) and was an independent prognostic factor for both DFS (hazard ratio [HR] = 2.04; 95% confidence interval [95% CI] 1.30-3.18, P = 0.0018) and OS (HR = 3.54; 95%CI 1.53-8.23, P = 0.003) in stage I-II breast cancer patients.

Conclusion: To our knowledge, this is the first study to recommend the optimal cut-off value of TOP2A expression in breast cancer. The TOP2A expression is significantly correlated with HER2 status, Ki67 index, tumor size, histologic grade and HR status, and could be a surrogate indicator for poor prognosis of early breast cancer.

Keywords: Breast cancer; Cut-off value; Prognosis; Prospective analysis; TOP2A protein.

MeSH terms

  • Antigens, Neoplasm / analysis
  • Antigens, Neoplasm / genetics
  • Breast Neoplasms*
  • DNA Topoisomerases, Type II* / genetics
  • DNA-Binding Proteins / genetics
  • Disease-Free Survival
  • Female
  • Humans
  • Ki-67 Antigen / genetics
  • Ki-67 Antigen / metabolism
  • Poly-ADP-Ribose Binding Proteins* / genetics
  • Prognosis
  • Receptor, ErbB-2 / metabolism

Substances

  • Antigens, Neoplasm
  • DNA-Binding Proteins
  • Ki-67 Antigen
  • Poly-ADP-Ribose Binding Proteins
  • Receptor, ErbB-2
  • DNA Topoisomerases, Type II
  • TOP2A protein, human